Innovating Works

MammoScreen

Financiado
Innovative and safe microwave-based imaging technology to make breast cancer scr...
Innovative and safe microwave-based imaging technology to make breast cancer screening more accurate, inclusive and female-friendly Breast cancer (BC) is the most common cancer in women worldwide, affecting 1 in 8 women. The figures from WHO’s International Agency for Research on Cancer estimate that in 2020 worldwide cases of breast cancer accounted for 24% o... Breast cancer (BC) is the most common cancer in women worldwide, affecting 1 in 8 women. The figures from WHO’s International Agency for Research on Cancer estimate that in 2020 worldwide cases of breast cancer accounted for 24% of all cancers in women (2.26 million women and 685,000 deaths globally). Mammography is the gold standard technology for breast screening, which has been demonstrated through different randomized controlled trials to reduce breast cancer mortality. However, it has limitations and potential harms, such as the use of ionizing radiation, breast compression and performance restrictions due to the intrinsic nature of X-rays. In particular, breast density is a restrictive property that can prevent breast cancer detection in mammograms of women with radiographically dense breasts. Other existing techniques (MRI, Ultrasound, biopsy) also suffer from drawbacks. The overall aim of the MammoScreen proposal is to generate evidence about the use of MammoWave (a technology developed by UBT) as screening technique in population-based programs promoted by National or Regional Health Systems, to reach a revolution in breast screening. To do so, the consortium aims to confirm that MammoWave reaches sensitivity>90% and specificity>95% in BC detection on 10000 study participants undergoing regular screening programs. MammoWave uses safe non-invasive and non-ionizing microwave signals, does not apply any compression to the breast and is very effective with dense breasts. Hence it can extend the breast screening to younger women aged 20-49 (98 million women in Europe). This group accounts for ~30% of breast cancers in 2020. A comprehensive health economic assessment will be undertaken in this project and innovative way to implement patient engagement approaches is sought. An effective policy makers’ engagement plan will be carried out to ensure that MammoWave is recommended as screening approach due to the benefits that it brings to women and healthcare systems. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening. ver más
30/11/2026
TLS
6M€
Duración del proyecto: 48 meses Fecha Inicio: 2022-11-28
Fecha Fin: 2026-11-30

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-28
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-MISS-2021-CANCER-02-01: Develop new methods and technologies for cancer screening and early detection
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 6M€
Líder del proyecto
FONDAZIONE TOSCANA LIFE SCIENCES No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5